Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. reported modest revenue growth but continued heavy losses for the quarter and six months ended June 30, 2026. Revenue was $994 thousand for the quarter and $2.7 million year-to-date, up 7% and 36% respectively, mainly from collaboration work in Sustainable Ingredients. Operating expenses fell sharply due to cost-cutting, with R&D down 30% and SG&A down 19% in the quarter, and no goodwill impairment charge in 2026 versus 2025.
Despite lower expenses, the business remains deeply loss-making. Net loss was $22.1 million for the quarter and $43.4 million year-to-date, and accumulated deficit reached $901.6 million. A large related-party royalty liability of $253.5 million generated $18.6 million of interest expense in six months. Cash used in operations was $20.9 million, leaving $20.4 million of cash against $14.4 million of current liabilities.
Management states that these factors raise substantial doubt about the company’s ability to continue as a going concern without new capital. Cibus raised roughly $33.4 million net in two follow-on equity offerings and established a $50 million ATM facility, and targets an annual cash usage run-rate of about $35 million exiting 2026 while advancing key Rice and Sustainable Ingredients programs.
Cibus, Inc. reported second quarter 2026 results and a business update centered on commercial execution in Rice herbicide-tolerance traits and its Sustainable Ingredients program. The company expanded its relationship with Rice customer Interoc from two to five traits and now has seven Rice seed-company customers across Latin America and the United States, targeting initial Latin American launches around 2028 and a U.S. launch aligned with a 2029 herbicide-registration timeline.
Cibus highlighted favorable regulatory developments, including U.S. treatment of its traits as conventional breeding, completion of an FDA review of an altered-lignin Alfalfa trait, and new European Union legislation generally treating precisely edited, non-transgenic crops as conventionally bred. Cash and cash equivalents were $20.4 million as of June 30, 2026; the company expects this to fund operations into early in the first quarter of 2027. Quarterly net cash usage declined, and management now targets an annual net cash usage run-rate of about $35 million exiting 2026. Revenue was $0.994 million, R&D expense fell to $8.5 million, SG&A to $5.4 million, and net loss narrowed to $22.1 million, compared with $26.6 million a year earlier.
Cibus, Inc. CEO Craig Wichner reported new equity compensation awards. He received 894,309 shares of Class A Common Stock as a grant, with these restricted stock units vesting in four equal 25% installments on each of the first four anniversaries of the grant date.
He was also granted options covering 1,047,620 shares of Class A Common Stock at an exercise price of $1.23 per share. These options vest 25% per year over the first four anniversaries of the grant date and expire on June 8, 2036. All holdings reported are direct.
Cibus, Inc. appointed Craig Wichner as Chief Executive Officer as part of its succession plan, effective June 8, 2026. Wichner, formerly a director, brings experience as founder and managing partner of Farmland LP, a U.S. farmland investment firm with more than $350 million in assets and over 19,000 acres under management.
Interim CEO Peter Beetham returned to his prior role as President and Chief Operating Officer, and both he and Wichner resigned from the Board, reducing the Board size to seven directors. Wichner’s employment agreement sets an initial base salary of $650,000, bonus eligibility, severance protections, and change-in-control benefits.
On June 8, 2026, Wichner received a restricted stock unit award valued at $1.1 million and a stock option award also valued at $1.1 million, each vesting in four equal annual installments. The company highlighted its focus on executing near-term commercialization targets and capital strategy under the new leadership.
Cibus, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Of 76,345,736 shares of Class A common stock entitled to vote as of the April 6, 2026 record date, 53,072,072 shares, or about 69.52%, were represented, establishing a quorum.
Stockholders elected nine directors, including Mark Finn and Peter Beetham, to one-year terms. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026.
Cibus, Inc. director Mark Terrence Finn reported receiving a grant of stock options. He was awarded 77,586 options to buy Class A common stock at an exercise price of $1.39 per share. The options vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual shareholder meeting, subject to his continued service. The options expire on June 2, 2036, and were granted as compensation rather than through any open-market transaction.
Cibus, Inc. director August J. Moretti received a grant of 77,586 stock options on June 2, 2026 to buy Class A Common Stock at an exercise price of $1.39 per share. The options vest in full after one year or at the next annual shareholder meeting and expire on June 2, 2036.
Cibus, Inc. director Rory B. Riggs reported receiving a grant of stock options. The award covers 77,586 options to buy Class A common stock at an exercise price of $1.39 per share, expiring on June 2, 2036.
According to the terms, these options vest in full, subject to his continued service, on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual meeting of shareholders. Following this grant, Riggs holds 77,586 derivative securities directly.
Cibus, Inc. director Gerhard Prante reported an equity compensation grant involving the company’s Class A common stock. He acquired 64,748 shares at a stated price of $0.00 per share as a grant or award, rather than an open-market purchase. Following this award, his directly held position increased to 104,945 shares of Class A common stock.
The footnote explains that these are Restricted Stock Units that vest in full, subject to his continued service as a director, on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. This shows the grant is tied to ongoing board service rather than a discretionary market transaction.
Lehmann Jean-Pierre Jules reported acquisition or exercise transactions in this Form 4 filing.
Cibus, Inc. director Jean-Pierre Jules Lehmann received an award of 64,748 shares of Class A Common Stock in the form of Restricted Stock Units. The award carries a price of $0.00 per share, indicating equity compensation rather than a market purchase. Following this grant, Lehmann directly holds 763,904 shares. The RSUs vest in full, subject to his continued service, on the earlier of one year from the grant date or the company’s next annual meeting of shareholders.